Vantage logo

Ascendis shoots higher on pivotal win 

Shares in the company surge after its weekly growth hormone treatment proves superior to daily injections, raising broader hopes for Ascendis’s long-acting technology.

Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.